Multiple sclerosis (MS) is a nervous system disease which affects spinal cord and the brain. MS damages the myelin sheath. Myelin sheath is a term which exemplifies that material which surrounds and protects human nerve cells. This damage blocks messages between brain and the body and leads to the symptoms of MS. Some of the major symptoms of MS include thinking and memory problems, visual disturbances, problem in coordination and balancing of the body and muscle weakness.
MS affects women more than men. The disease often occurs between age group of 20-40. MS is mainly divided into four types. They are relapsing-remitting MS, progressive-relapsing MS, secondary-progressive MS and primary-progressive MS. Relapsing-remitting MS is the most common form of the disease. It accounts about 85% of the total MS cases. Secondary-progressive is associated with the initial period of relapsing-remitting disease. Approximately, 50% of people suffering with relapsing remitting MS would develop this form of the disease. Progressive-relapsing MS is rare and about 5% of the total MS cases. Primary-progressive MS accounts 10% of the total MS cases.
In terms of geographic, North America dominates the global MS drugs market. The U.S. represents the largest market for MS drugs followed by Canada in North America. In Europe, France, Germany, Italy, Spain and the U.K. holds major share of MS drugs market. However, Asia is expected to show high growth rates in the next five years in global MS drugs market. This is due to many companies constructing their manufacturing and research facilities in the region. Developing regions have advantage over the developed regions due to low wages, availability of a large talent pool, less stringent environment and health and safety regulations. Japan, China and India are expected to be the fastest growing MS drugs markets in Asia.
In 2018, the global Multiple Sclerosis Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Multiple Sclerosis Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Multiple Sclerosis Drugs development in United States, Europe and China.
The key players covered in this study
GlaxoSmithKline
Novartis
Merck
Sanofi
Pfizer
Bayer
Teva Pharmaceutical
Abbvie
Biogen Idec
AB Science
Opexa
Market segment by Type, the product can be split into
Oral Drugs
Parenteral Drugs
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Multiple Sclerosis Drugs status, future forecast, growth opportunity, key market and key players.
To present the Multiple Sclerosis Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Multiple Sclerosis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Multiple Sclerosis Drugs . Industry analysis & Market Report on Multiple Sclerosis Drugs is a syndicated market report, published as Global Multiple Sclerosis Drugs Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Multiple Sclerosis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.